Hypoglycemic activity of brown seaweed (Sargassum plagiophyllum) kombucha bioactive compound in rat model type-2 of diabetes

Hyperglycemia is a condition of increased blood glucose with out of normal limits criteria associated with diabetes mellitus. Uncontrolled hyperglycemia is one of the causes of complications in diabetes mellitus sufferers. Sargassum plagiophyllum is one of brown seaweed that contains many bioactive...

Full description

Saved in:
Bibliographic Details
Main Authors: Priambodo Ahmad Faris, Martati Erryana, Firdaus Muhamad
Format: Article
Language:English
Published: EDP Sciences 2025-01-01
Series:BIO Web of Conferences
Online Access:https://www.bio-conferences.org/articles/bioconf/pdf/2025/05/bioconf_icgrc2025_02009.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hyperglycemia is a condition of increased blood glucose with out of normal limits criteria associated with diabetes mellitus. Uncontrolled hyperglycemia is one of the causes of complications in diabetes mellitus sufferers. Sargassum plagiophyllum is one of brown seaweed that contains many bioactive compounds which are useful as hypoglycemic agents. The kombucha fermentation method is used to reduce structural complexity, thereby increasing the bioavailability of bioactives. This study aims to evaluate the administration of S. plagiophyllum kombucha (SK) to the blood profile of type 2 diabetes mellitus (DM2) rats treated with a 21% highfructose diet (HFD) with normal feed. S. plagiophyllum was obtained from Talango, Sumenep, Madura Island, East Java Province. 2-month-old male Rattus norvegicus was used as a model animal. The study consisted of 5 groups, including negative control, positive control (DM2), DM2 + SK 1.5 mL/250 g bw once a day, DM2 + SK 1.5 mL/250 g bw twice a day, and DM2 + SK 1, 5 mL/250 g bw three times a day. Animal model research was carried out for 2 months. The study’s conclusion shows that S. plagiophyllum kombucha has bioactive compounds as hypoglycemic agents and contributes to improving body weight, fasting blood glucose (FBG), lipid profiles, insulin, and MDA in type-2 diabetes rats model.
ISSN:2117-4458